Barbara White, MD, joined SFJ Pharmaceuticals® as Chief Medical Officer in September 2021, and became President and CEO in 2024. Barbara has 18 years of experience in the pharmaceutical industry, following a productive career as a physician scientist in academia. Barbara’s industry experience includes pre-clinical drug development, Phase 1-3 and post-approval clinical development, translational medicine, and medical affairs. Prior to joining SFJ, Barbara was Chief Medical Office and Head of Research at Corbus Pharmaceuticals, Inc., SVP and Head of R&D at Stiefel, a GSK company, and held leadership roles at UCB, MedImmune, and Amgen.

Before starting her pharmaceutical career, Barbara was Professor of Medicine and Vice Chair for Research, Department of Medicine, at the University of Maryland School of Medicine. Barbara received her medical degree from the University of Pennsylvania School of Medicine and is board certified in internal medicine, rheumatology and allergy/clinical immunology. She did postdoctoral studies in basic cellular immunology at the National Cancer Institute, NIH. Barbara was recently elected Master, American College of Rheumatology.